BackNeurocrine Biosciences Overview

Neurocrine Biosciences Goodwill

Track Neurocrine Biosciences's goodwill ($500M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Goodwill
$500.60M

Peer trimmed avg / median

Loading

Neurocrine Biosciences Goodwill History

Loading

Neurocrine Biosciences vs. peers: Goodwill Comparison

Loading

Neurocrine Biosciences Goodwill Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Neurocrine Biosciences (NBIX) FAQ

Neurocrine Biosciences (NBIX) currently reports a goodwill of $500M as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Neurocrine Biosciences's goodwill history and peer comparisons.

Neurocrine Biosciences's goodwill changed from $0 to $500M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neurocrine Biosciences reported $500M in goodwill as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current goodwill of $500M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neurocrine Biosciences, and consider following NBIX for alerts when major investors trade the stock.

Neurocrine Biosciences is classified in the Healthcare sector. On goodwill, it currently shows $500M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBIX with unrelated industries.